Congress held two separate hearings on implementation of the 21st Century Cures Act one year after the legislation was signed into law.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On December 12, ASCO held a webinar, Quality Payment Program: Preparing for 2018, Surviving in 2017, on data reporting under the Merit-Based Incentive Payment System (MIPS) in 2017 and 2018. Anyone who missed this event should bookmark ASCO’s MACRA resources page, where a recording and slides from the webinar will be posted.
Congress passed two-week continuing resolution to keep the government funded at current levels through December 22, 2017.
ASCO is accepting applications for its one-year Health Policy Fellowship, which provides a meaningful and unique opportunity for the Society’s members and volunteers to develop expertise in health policy.
On December 12, from 4:00 – 5:30 PM ET, ASCO will host a free webinar Quality Payment Program: Preparing for 2018, Surviving in 2017. The webinar will discuss 2017 and 2018 data reporting under the Merit-Based Incentive Payment System (MIPS). MIPS practices must report on one 2017 quality measure to avoid a four percent Medicare reimbursement penalty in 2019. The webinar will also include a demo of the QOPI Reporting Registry, which practices can use for 2017 MIPS reporting.
We are deeply concerned about the sequestration cuts that would be triggered by passage of the Tax Cuts and Jobs Act. The core mission of the American Society of Clinical Oncology (ASCO) is to ensure that cancer patients have meaningful access to high-quality cancer care. We fear that the current proposal will harm patients with cancer by reducing access to care, a situation that could adversely impact treatment needed to extend and save patients' lives.
On November 30, 2017, the Food and Drug Administration granted marketing approval to the FoundationOne CDx (F1CDx, Foundation Medicine, Inc.), a next generation sequencing (NGS) based in vitro diagnostic (IVD) to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.
On December 1, 2017, the Food and Drug Administration approved Ogivri (trastuzumab-dkst, Mylan) as a biosimilar to Herceptin (trastuzumab, Genentech, Inc.) for the treatment of patients with HER2-overexpressing breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
ASCO and seven other medical societies sent a letter to the leaders of key congressional committees to ask lawmakers to take action this year to remove Part B drug payments from the Merit-based Incentive Payment System (MIPS) score adjustment.
A report released today by the National Academies of Sciences, Engineering, and Medicine underscores the imperative our nation faces to address the affordability of drugs for medical conditions that have long-been deemed untreatable. Nowhere is this imperative more urgent than with the new generation of cancer drugs that is giving hope to the millions of Americans who face a cancer diagnosis each year—while creating formidable barriers to access due to the high cost of these agents.
A new Physician Assistant (PA)-based study finds that despite personal satisfaction in the oncology specialty, high rates of burnout –over one third of PAs (34.8%)—are common. These findings reveal important factors that could help to decrease burnout and improve the oncology workforce dynamics, including the relationship between PAs, collaborating physicians, and the care team. The study was published today in the Journal of Oncology Practice (JOP).
New advertisements from tobacco companies on the dangers of smoking began running this week as a result of a lawsuit going back nearly two decades. The ads feature “corrective statements,” intended to right false claims on the effects of smoking previously made by tobacco companies.
On December 5, from 1pm – 2pm ET, the U.S. Federal Drug Administration’s (FDA) Division of Drug Information (DDI) is hosting a complimentary webinar entitled, Overview of the Regulatory Framework and the Development and Approval of Biosimilar Products in the U.S. This is part of a series of educational webinars designed to help health care professionals better understand FDA regulation and medication safety.
ASCO has relaunched its “Cancer Progress Timeline” with many new and more recent milestones in cancer research and a focus on research that was supported by federal funding.
Members of the Cancer Leadership Council, including ASCO, raised concerns that the tax bill under consideration by the U.S. Senate would trigger sequestration and threaten cuts to Medicare.